| 1 |
钱桂生. 肺癌不同病理类型发病率的变化情况及其原因[J/CD]. 中华肺部疾病杂志(电子版), 2011, 4(1): 1-5.
|
| 2 |
Jemal A, Bray F, Center MM, et al. Global cancer statistics[J]. CA Cancer J Clin, 2011, 61(2): 69-90.
|
| 3 |
Ferlay J, Shin HR, Bray F, et al. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008[J]. Int J Cancer, 2010, 127(12): 2893-2917.
|
| 4 |
2015美国国家综合癌症网络(NCCN)指南：肺癌的全身治疗[J]．中国全科医学，2015(18): 2126.
|
| 5 |
Gridelli C, Ardizzoni A, Douillard JY, et al. Recent issues in first-line treatment of advanced non-small-cell lung cancer: Results of an international expert panel meeting of the Italian association of thoracic oncology[J]. Lung cancer, 68(3): 319-331.
|
| 6 |
Kuan FC, Kuo LT, Chen MC, et al. Overall survival benefits of first-line EGFR tyrosine kinase inhibitors in EGFR-mutated non-small-cell lung cancers: a systematic review and meta-analysis[J]. Br J Cancer, 2015, 113(10): 1519-1528.
|
| 7 |
Rosell R, Moran T, Queralt C, et al. Screening for epidermal growth factor receptor mutations in lung cancer[J]. N Engl J Med, 2009, 361(10): 958-967.
|
| 8 |
Yang JC, Wu YL, Schuler M, et al. Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): analysis of overall survival data from two randomised, phase 3 trials[J]. Lancet Oncol, 2015, 16(2): 141-151.
|
| 9 |
Jackman DM, Yeap BY, Sequist LV, et al. Exon 19 deletion mutations of epidermal growth factor receptor are associated with prolonged survival in non-small cell lung cancer patients treated with gefitinib or erlotinib[J]. Clin Cancer Res, 2006, 12(13): 3908-3914.
|
| 10 |
Travis WD, Brambilla E, Muller-Hermelink HK, et al. World Health Organization classification of tumours. Pathology and genetics of tumours of the lung pleurthymus and heart[M]. Lyon: IARC Press, 2004.
|
| 11 |
钱桂生. 为提高我国呼吸系统疾病的诊治水平而努力[J/CD]. 中华肺部疾病杂志(电子版), 2012, 5(1): 1-3.
|
| 12 |
邹晶，徐兴祥，王大新，等. 肺癌放化疗"实时"疗效评估方法的研究进展[J/CD]. 中华肺部疾病杂志(电子版), 2013, 6(4): 360-363.
|
| 13 |
Zhang Y, Sheng J, Kang S, et al. Patients with exon 19 deletion were associated with longer progression-free survival compared to those with L858R mutation after first-line EGFR-TKIs for advanced non-small cell lung cancer: a meta-analysis[J]. PLoS One, 2014, 9(9): e107161.
|
| 14 |
Gazdar AF, Shigematsu H, Herz J, et al. Mutations and addiction to EGFR: The achilles 'heal’ of lung cancers[J]. Trends Mol Med, 2004, 10(10): 481-486.
|
| 15 |
Yu HA, Arcila ME, Hellmann MD, et al. Poor response to erlotinib in patients with tumors containing baselineEGFR T790M mutations found by routine clinical molecular testing[J]. Ann Oncol, 2014, 25(2): 423-428.
|
| 16 |
Chou TY, Chiu CH, Li LH, et al. Mutation in the tyrosine kinase domain of epidermal growth factor receptor is a predictive and prognostic factor for gefitinib treatment in patients with non-small cell lung cancer[J]. Clin Cancer Res, 2005, 11(10): 3750-3757.
|
| 17 |
Mitsudomi T, Yatabe Y. Mutations of the epidermal growth factor receptor gene and related genes as determinants of epidermal growth factor receptor tyrosine kinase inhibitors sensitivity in lung cancer[J]. Cancer Sci, 2007, 98(12): 1817-1824.
|
| 18 |
Wu JY, Wu SG, Yang CH, et al. Lung cancer with epidermal growth factor receptor exon 20 mutations is associated with poor gefitinib treatment response[J]. Clin Cancer Res, 2008, 14(15): 4877-4882.
|
| 19 |
Arrieta O, Cardona AF, Corrales L, et al. The impact of common and rare EGFR mutations in response to EGFR tyrosine kinase inhibitors and platinum-based chemotherapy in patients with non-small cell lung cancer[J]. Lung Cancer, 2015, 87(2): 169-175.
|
| 20 |
Ellis PM, Coakley N, Feld R, et al. Use of the epidermal growth factor receptor inhibitors gefitinib, erlotinib, afatinib, dacomitinib, and icotinib in the treatment of non-small-cell lung cancer: a systematic review[J]．Curr Oncol, 2015, 22(3): 183-215.
|
| 21 |
Shi L, Tang J, Tong L, et al. Risk of interstitial lung disease with gefitinib and erlotinib in advanced non-small cell lung cancer: a systematic review and meta-analysis of clinical trials[J]. Lung Cancer, 2014, 83(2): 231-239.
|